Streetbeat News

Stock Prices

CHH

Choice Hotels International Inc (CHH) has provided an update on its strategy and 2023 and 2024 guidance. The company is expanding its franchise business and has exceeded its synergy targets with the integration of Radisson Hotels Americas. CHH has opened 107 hotels in 2023, a 39% increase YoY. The company reiterated its 2023 outlook and expects a 10% YoY growth in adjusted EBITDA for 2024. CHH also repurchased around 1.8 million shares worth over $220 million in H1 2023.

Portfolio Pulse from Lekha Gupta

July 11, 2023 | 1:40 pm

ELOX

Shares of Eloxx Pharmaceuticals were halted on a circuit breaker to the upside, with the stock now up by 31.7%.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:39 pm

BRTX

BioRestorative Therapies Inc (BRTX) shares dropped by 17.13% after the company announced a $2.1 million registered direct offering. The offering is for the sale of 685,033 shares at $3.03 per share. The proceeds will be used for clinical trials, pre-clinical research and development, and general corporate purposes.

Portfolio Pulse from Henry Khederian

July 11, 2023 | 1:36 pm

BTCUSD

ETHUSD

WBTCUSD

XECUSD

Bitcoin (BTC) and Ethereum (ETH) traded higher, with BTC above the $30,400 level and ETH above the $1,800 mark. Wrapped Bitcoin (WBTC) was the top gainer over the prior 24 hours, while eCash (XEC) was the biggest loser. The global crypto market cap rose to $1.18 trillion, recording a 24-hour gain of 0.9%. Other notable gainers include Solana (SOL), Compound (COMP), Polygon (MATIC), and Mina (MINA). Losers include Nexo (NEXO), Monero (XMR), Toncoin (TON), and Algorand (ALGO).

Portfolio Pulse from Lisa Levin

July 11, 2023 | 1:36 pm

CING

Cingulate Inc (NASDAQ:CING) shares are trading higher following the announcement of positive topline results from its Phase 3 adult trial of lead candidate, CTx-1301, for attention-deficit/hyperactivity disorder (ADHD). The data showed a significant trend in improving ADHD symptoms. The company plans to initiate its pivotal Phase 3 fixed-dose pediatric and adolescent study this month and a dose-optimization onset and duration trial in pediatric patients in August 2023. Assuming positive results, Cingulate plans to submit a New Drug Application for CTx-1301 in mid-2024.

Portfolio Pulse from Vandana Singh

July 11, 2023 | 1:33 pm

IOVA

Iovance Biotherapeutics Inc's shares are trading lower after the company announced the pricing of a public offering of 20 million shares at $7.50 per share, expected to raise approximately $150 million. The proceeds will be used to fund preparations for the commercial launch of lifileucel, support the development of the company's pipeline candidates, and support Proleukin integration activities. Despite the drop, Truist Securities and Chardan Capital analysts reiterated a Buy rating for Iovance, with price targets of $17 and $29 respectively.

Portfolio Pulse from Adam Eckert

July 11, 2023 | 1:30 pm

BGNE

Novartis has terminated its licensing deal with BeiGene to develop, manufacture and commercialize ociperlimab, causing BeiGene shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:29 pm

F

GM

TSLA

A Twitter poll conducted by CarDealershipGuy suggests that 49% of respondents believe that electric vehicles (EVs) will hold a market share of 30% or more in the US by 2030. The current EV market share for new vehicles in the US is between 7% and 8%. The poll results could be positive for companies like Tesla, Ford, and General Motors, which are transitioning to EVs. However, supply and demand for EVs will need to increase for market share to grow.

Portfolio Pulse from Chris Katje

July 11, 2023 | 1:28 pm

ASAN

AXR

NVCT

Insider trades were noted in Asana, Inc. (ASAN), AMREP Corporation (AXR), and Nuvectis Pharma, Inc. (NVCT). ASAN's CEO acquired 160,000 shares, indicating confidence in the company following better-than-expected Q1 results. AXR's 10% owner bought 25,361 shares after a sharp increase in Q3 EPS. NVCT's 10% owner purchased 8,948 shares as the company posted a narrower-than-expected quarterly loss.

Portfolio Pulse from Lisa Levin

July 11, 2023 | 1:13 pm

HOOD

Robinhood Markets Inc (NASDAQ:HOOD) shares are trading higher after JMP Securities analyst Devin Ryan reiterated a Market Outperform rating and maintained a $25 price target. The stock has seen increased retail investor attention, being among the most mentioned on Reddit's r/wallstreetbets and Stocktwits. Robinhood is set to report Q2 financial results on Aug. 2, with an expected loss of 1 cent per share on quarterly revenue of $470.28 million.

Portfolio Pulse from Adam Eckert

July 11, 2023 | 1:12 pm